AAD VMX 2021: Patient Experiences Of Telemedicine Consults For Hidradenitis Suppurativa
Patients with hidradenitis suppurativa were asked about their satisfaction regarding telemedicine...
Read More
Meeting Coverage
AAD VMX 2021: Alopecia Areata And The Risk Of Severe COVID-19
First author: Niki Nourmohammadi The COVID-19 pandemic has been associated with psychological...
Read More
AAD VMX 2021: Emotional Impact Of Alopecia In Breast Cancer Survivors
Presented by: Prof. Mario Lacouture, Memorial Sloan Kettering Cancer Centre As advances in breast...
Read More
AAD VMX 2021: Maskne: Side Effects Of Facial Masks During COVID-19
A side effect that might not be the first to think about in the COVID-19 pandemic concerns wearing...
Read More
AAD VMX 2021: Why Teledermatology Is Here To Stay
Presented by: Jules Lipoff (University of Pennsylvania), Elizabeth Jones (Thomas Jefferson...
Read More
AAD VMX 2021: Latest News On Sunscreens: Updates From 2021
The importance of sunscreen has been acknowledged globally. Recent topics of discussion include...
Read MoreAAN 2021: Significant Discrepancy Found in General vs Neuroradiologists MRI Reporting of MS
Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI) and the support of dedicated multidisciplinary teams (MDTs). While decisions...
Read More
AAN 2021: Race May Affect Response to Anti-CD20 Therapy for MS, NMOSD
For patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD)...
Read More2021 AAN Annual Meeting Kick-Off!
Due to the COVID-19 pandemic, the 2021 American Academy of Neurology Annual Meeting, the world’s premier neurology meeting, will be held in a fully virtual format from April 17-22. It will include: Over 90 expert-led CME...
Read MoreAAN 2021: Identifying distinct cognitive phenotypes in multiple sclerosis
Cognitive impairment is a common and disabling feature of multiple sclerosis (MS), but a precise characterization of cognitive phenotypes in MS patients is still lacking. This study identified five cognitive phenotypes:...
Read MoreAAN 2021: Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis
The study team compared disability accrual in primary and secondary progressive multiple sclerosis (PPMS, SPMS) in the international MSBase cohort, using multivariable survival models, and applying objective diagnostic criteria...
Read MoreAAN 2021: Dual Tasking In Patients With MS
Patients with MS may have difficulty performing double task (DT) while walking or causing interference. More research is needed in order to define the role of disability degree in the severity of the interference produced in the...
Read MoreAAN 2021: Influencing And Optimizing The Management Of Patients With MS
Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI). As physicians, decisions are influenced by the reporting prowess of...
Read More
AACR 2021: New Agent Improves Survival in Metastatic Uveal Melanoma
Five-month advantage observed with tebentafusp The novel bispecific fusion protein tebentafusp...
Read More
AACR 2021: Addition of Copanlisib Improves Lymphoma Outcomes
Disease progression slowed with copanlisib/rituximab combo The combination of copanlisib plus...
Read MoreMET Kinase Inhibitors Vs Sunitinib For pRCC
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...
Read MoreFollow-Up on Phase III JAVELIN Renal Trial: A+Ax vs S
Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101 In the phase III JAVELIN Renal 101...
Read MoreOutcomes Of First-Line Immuno-Oncology Combo in mRCC
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...
Read MoreTivozanib In Patients With aRCC
TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. The TIVO-3 study enrolled subjects with mRCC who failed two or three prior systemic regimens, one of...
Read MoreGenitourinary Cancers Symposium: New therapy prolongs survival for patients with urothelial carcinoma
Enfortumab vedotin (EV) will likely become the new standard of care for treating patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC). A recent phase 3 trial showed that treatment with...
Read More